[
  {
    "ts": null,
    "headline": "Acuitas Sues GSK Seeking Declaratory Judgment Of Invalidity And Non-Infringement Of MRNA Vaccine Patents",
    "summary": "As we previously reported, in April of last year, GlaxoSmithKline Biologicals SA and GlaxoSmithKline LLC brought a lawsuit against Pfizer and BioNTech in the District Court for the District of...",
    "url": "https://finnhub.io/api/news?id=735d1546f5199e565c7f4c25950d0c6019e87e6f1d8ad601bc577ac90418feb1",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736939527,
      "headline": "Acuitas Sues GSK Seeking Declaratory Judgment Of Invalidity And Non-Infringement Of MRNA Vaccine Patents",
      "id": 132400234,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "As we previously reported, in April of last year, GlaxoSmithKline Biologicals SA and GlaxoSmithKline LLC brought a lawsuit against Pfizer and BioNTech in the District Court for the District of...",
      "url": "https://finnhub.io/api/news?id=735d1546f5199e565c7f4c25950d0c6019e87e6f1d8ad601bc577ac90418feb1"
    }
  },
  {
    "ts": null,
    "headline": "BridgeBio Pharma Is A Buy On Dips After Attruby's FDA Approval",
    "summary": "Attruby's approval makes BridgeBio Pharma a competitor to Vyndaqel, with significant potential for growth and milestone payments. Read my BBIO stock thesis.",
    "url": "https://finnhub.io/api/news?id=603de51c897277e73f0859e2d8e7aa0d776695a26c886933a62a76d60de1e496",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736933400,
      "headline": "BridgeBio Pharma Is A Buy On Dips After Attruby's FDA Approval",
      "id": 132399965,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1186545957/image_1186545957.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Attruby's approval makes BridgeBio Pharma a competitor to Vyndaqel, with significant potential for growth and milestone payments. Read my BBIO stock thesis.",
      "url": "https://finnhub.io/api/news?id=603de51c897277e73f0859e2d8e7aa0d776695a26c886933a62a76d60de1e496"
    }
  },
  {
    "ts": null,
    "headline": "Vaxcyte Aims To Outshine Pfizer With Bold VAX-31 Strategy",
    "summary": "Vaxcyte's robust financial position supports its strategic flexibility and extended timelines. Read more to see why I rate PCVX stock as a buy.",
    "url": "https://finnhub.io/api/news?id=8abfda3931b400660ffe40ffc761cb5cac2b4521cf8522657809e87d141614f4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736925320,
      "headline": "Vaxcyte Aims To Outshine Pfizer With Bold VAX-31 Strategy",
      "id": 132399353,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1316007813/image_1316007813.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Vaxcyte's robust financial position supports its strategic flexibility and extended timelines. Read more to see why I rate PCVX stock as a buy.",
      "url": "https://finnhub.io/api/news?id=8abfda3931b400660ffe40ffc761cb5cac2b4521cf8522657809e87d141614f4"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer cuts stake in Haleon to 7% in GBP2.5 billion share sale",
    "summary": "Pfizer Inc sold 700 million shares in Haleon PLC, as planned, more than halving its remaining stake, placing agent JPMorgan Securities PLC confirmed on Wednesday.The shares were sold at 357 pence,...",
    "url": "https://finnhub.io/api/news?id=31618e64584e70f3c625fddf23f7ed1eff2f00bc5e84d51cf9a3eaa7c1602317",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736912656,
      "headline": "Pfizer cuts stake in Haleon to 7% in GBP2.5 billion share sale",
      "id": 132398258,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "Pfizer Inc sold 700 million shares in Haleon PLC, as planned, more than halving its remaining stake, placing agent JPMorgan Securities PLC confirmed on Wednesday.The shares were sold at 357 pence,...",
      "url": "https://finnhub.io/api/news?id=31618e64584e70f3c625fddf23f7ed1eff2f00bc5e84d51cf9a3eaa7c1602317"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Sells 700 Million Haleon Shares for $3.05 Billion",
    "summary": "By Ian Walker Pfizer has sold 700 million shares in British consumer-healthcare business Haleon for 2.50 billion pounds, equivalent to US$3.05 billion, it said in a statement. The U.S....",
    "url": "https://finnhub.io/api/news?id=3d6c7cabca6dc4d4347a6c62ea72bc35a5303299a1cba3cf015a25b7dda19ac2",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1736909888,
      "headline": "Pfizer Sells 700 Million Haleon Shares for $3.05 Billion",
      "id": 132398023,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "By Ian Walker Pfizer has sold 700 million shares in British consumer-healthcare business Haleon for 2.50 billion pounds, equivalent to US$3.05 billion, it said in a statement. The U.S....",
      "url": "https://finnhub.io/api/news?id=3d6c7cabca6dc4d4347a6c62ea72bc35a5303299a1cba3cf015a25b7dda19ac2"
    }
  }
]